Exane Derivatives Portfolio holdings
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Stellantis
STLA
|
+$10.1M |
| 2 |
Vale
VALE
|
+$2.39M |
| 3 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$2.33M |
| 4 |
Coca-Cola
KO
|
+$2.2M |
| 5 |
Wells Fargo
WFC
|
+$1.58M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street Energy Select Sector SPDR ETF
XLE
|
+$13.6M |
| 2 |
iShares MSCI Turkey ETF
TUR
|
+$7.85M |
| 3 |
iShares MSCI Taiwan ETF
EWT
|
+$6.97M |
| 4 |
Logitech
LOGI
|
+$5.93M |
| 5 |
UBS Group
UBS
|
+$5.5M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 20.54% |
| 2 | Consumer Discretionary | 15.45% |
| 3 | Healthcare | 13.48% |
| 4 | Technology | 13.47% |
| 5 | Financials | 10.95% |
Similar funds
Exane Derivatives's Q4 2020 Portfolio in Review
As of Q4 2020, Exane Derivatives held 889 positions worth $340M, down 1.5% from $345M the previous quarter. Its ten largest holdings account for 23% of the portfolio.
Exane Derivatives withdrew a net $28M in Q4 2020, closing 64 positions and reducing 255 holdings. Its most notable exit was ProShares S&P 500 Dividend Aristocrats ETF, an estimated $2.55M position sold in full.
By sector, the portfolio is most concentrated in Miscellaneous at 21% of assets, down from 37% a quarter earlier, followed by Consumer Discretionary and Healthcare.
Against the trend, Exane Derivatives opened a new position in Vale worth $3.01M.
- Exane Derivatives's largest Q4 2020 buy was Vale: 179,430 shares worth $3.01M.
- Exane Derivatives added most to Stellantis in Q4 2020, an estimated $10.1M increase.
- Exane Derivatives's biggest Q4 2020 reduction was State Street Energy Select Sector SPDR ETF, cutting an estimated $13.6M.
- Exane Derivatives fully exited ProShares S&P 500 Dividend Aristocrats ETF in Q4 2020, selling an estimated $2.55M.
- Exane Derivatives's ten largest holdings make up 23% of its $340M portfolio in Q4 2020.
- Exane Derivatives opened 138 new positions and closed 64 in Q4 2020.
- Exane Derivatives's portfolio value fell 1.5% quarter-over-quarter to $340M.
Based on Exane Derivatives's 13F filing for Q4 2020, filed 27 Jan 2021.